Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T

By GlobeNewswire

ST. LOUIS, MO, Aug. 24, 2021 (GLOBE NEWSWIRE) — Curium announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Cu-64 PSMA I&T, a radiopharmaceutical that binds to Prostate-Specific Membrane Antigen (PSMA) for use with Positron Emission Tomography (PET), for the detection and localization of metastatic prostate cancer. If approved, Curium expects that its Cu-64 PSMA I&T would be the first Cu-64 PSMA I&T agent for imag

…read more

Via:: Sports Headlines

      

Get 20% off hat purchases for ONLY $5! Join our LIDS Club @ lids.com.
%d bloggers like this: